Identification

Name
Estrone
Accession Number
DB00655  (APRD00588)
Type
Small Molecule
Groups
Approved
Description

Estrone, one of the major mammalian estrogens, is an aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone. It is produced in vivo from androstenedione or from testosterone via estradiol. It is produced primarily in the ovaries, placenta, and in peripheral tissues (especially adipose tissue) through conversion of adrostenedione. Estrone may be further metabolized to 16-alpha-hydroxyestrone, which may be reduced to estriol by estradiol dehydrogenase.

Structure
Thumb
Synonyms
  • 3-Hydroxy-1,3,5(10)-estratrien-17-one
  • Estrona
  • Estrone
  • Estronum
  • follicular hormone
  • Folliculin
  • Oestrone
Product Ingredients
IngredientUNIICASInChI Key
Sodium Estrone SulfateNot Available438-67-5VUCAHVBMSFIGAI-ZFINNJDLSA-M
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Estragyn Vaginal CreamCream0.1 %VaginalSearchlight Pharma Inc1987-12-31Not applicableCanada
Oestrilin Cones VaginauxSuppository.25 mgVaginalDesbergers LtÉe, Division Of Technilab Inc.1951-12-312004-08-09Canada
Oestrilin Creme Vaginale 1mgCream1 mgVaginalDesbergers LtÉe, Division Of Technilab Inc.1968-12-312004-08-23Canada
International/Other Brands
Estrone (Watson)
Categories
UNII
2DI9HA706A
CAS number
53-16-7
Weight
Average: 270.3661
Monoisotopic: 270.161979948
Chemical Formula
C18H22O2
InChI Key
DNXHEGUUPJUMQT-CBZIJGRNSA-N
InChI
InChI=1S/C18H22O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-16,19H,2,4,6-9H2,1H3/t14-,15-,16+,18+/m1/s1
IUPAC Name
(1S,10R,11S,15S)-5-hydroxy-15-methyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-2(7),3,5-trien-14-one
SMILES
[H][[email protected]@]12CCC(=O)[[email protected]@]1(C)CC[[email protected]]1([H])C3=C(CC[[email protected]@]21[H])C=C(O)C=C3

Pharmacology

Indication

For management of perimenopausal and postmenopausal symptoms.

Structured Indications
Pharmacodynamics

Estrone, a synthetically prepared or naturally occurring steroidal estrogen obtained from pregnant equine urine, is the primary circulating estrogen after menopause. Estrone is naturally derived from the peripheral conversion of androstenedione by an aromatase enzyme found in adipose tissues and is converted to estradiol in peripheral tissues. The estrogenic potency of estrone is one third that of estradiol. Estropipate is piperazine-stabilized estrone sulfate. Estrone, and estropipate are used to treat abnormalities related to gonadotropin hormone dysfunction, vasomotor symptoms, atrophic vaginitis, and vulvar atrophy associated with menopause, and for the prevention of osteoporosis due to estrogen deficiency.

Mechanism of action

Estrogens enter the cells of responsive tissues (e.g. female organs, breasts, hypothalamus, pituitary) where they interact with estrogen receptors. Hormone-bound estrogen receptors dimerize, translocate to the nucleus of cells and bind to estrogen response elements (ERE) of genes. Binding to ERE alters the transcription rate of affected genes. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) release from the anterior pituitary.

TargetActionsOrganism
AEstrogen receptor alpha
agonist
Human
UEstrogen receptor betaNot AvailableHuman
UAndrogen receptorNot AvailableHuman
UCytochrome P450 19A1Not AvailableHuman
USex hormone-binding globulinNot AvailableHuman
Absorption

43%

Volume of distribution
Not Available
Protein binding

> 95%

Metabolism

Hepatic.

Route of elimination
Not Available
Half life

19 hours

Clearance
Not Available
Toxicity

Symptoms of overdose include nausea and vomiting. Estrogen related side effects include nausea, breast tenderness, fluid retention and edema, headaches and/or migraines, chloasma and poor contact lens fit. Estrogen hormone deficiency is associated with breakthrough bleeding, hypomenorrhea, irritability, depression and menopausal symptoms. Withdrawal bleeds may occur in females.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Estrone MetabolismMetabolic
Androgen and Estrogen MetabolismMetabolic
17-Beta Hydroxysteroid Dehydrogenase III DeficiencyDisease
Androstenedione MetabolismMetabolic
Sulfate/Sulfite MetabolismMetabolic
Sulfite oxidase deficiencyDisease
Aromatase deficiencyDisease
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Estrone is combined with 1,10-Phenanthroline.Experimental
16-BromoepiandrosteroneThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Estrone.Investigational
19-norandrostenedioneThe serum concentration of 19-norandrostenedione can be increased when it is combined with Estrone.Experimental, Illicit
5-androstenedioneThe serum concentration of 5-androstenedione can be increased when it is combined with Estrone.Experimental, Illicit
AbciximabEstrone may decrease the anticoagulant activities of Abciximab.Approved
AbirateroneThe serum concentration of Estrone can be increased when it is combined with Abiraterone.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Estrone.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Estrone.Approved
AcenocoumarolEstrone may decrease the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Estrone.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Estrone.Approved
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Estrone.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Estrone.Approved, Withdrawn
AlclometasoneThe serum concentration of Alclometasone can be increased when it is combined with Estrone.Approved
AldesleukinEstrone may decrease the antineoplastic activities of Aldesleukin.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Estrone.Experimental, Investigational
AlgeldrateThe bioavailability of Estrone can be decreased when combined with Algeldrate.Approved, Experimental
AlmagateThe bioavailability of Estrone can be decreased when combined with Almagate.Experimental
AlmasilateThe bioavailability of Estrone can be decreased when combined with Almasilate.Approved, Experimental
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Estrone.Experimental
AloglutamolThe bioavailability of Estrone can be decreased when combined with Aloglutamol.Experimental
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with Estrone.Experimental
AluminiumThe bioavailability of Estrone can be decreased when combined with Aluminium.Approved
Aluminium acetoacetateThe bioavailability of Estrone can be decreased when combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe bioavailability of Estrone can be decreased when combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe bioavailability of Estrone can be decreased when combined with Aluminum hydroxide.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Estrone is combined with Ambenonium.Approved
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be increased when it is combined with Estrone.Experimental, Investigational
AmcinonideThe serum concentration of Amcinonide can be increased when it is combined with Estrone.Approved
AminophyllineThe serum concentration of Aminophylline can be increased when it is combined with Estrone.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Estrone.Approved
AmiodaroneThe metabolism of Estrone can be decreased when combined with Amiodarone.Approved, Investigational
Amphotericin BEstrone may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AnastrozoleThe therapeutic efficacy of Anastrozole can be decreased when used in combination with Estrone.Approved, Investigational
AncrodEstrone may decrease the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Estrone.Investigational
AndrostenedioneThe serum concentration of Androstenedione can be increased when it is combined with Estrone.Experimental, Illicit
AnecortaveThe serum concentration of Anecortave can be increased when it is combined with Estrone.Investigational
anecortave acetateThe serum concentration of anecortave acetate can be increased when it is combined with Estrone.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Estrone.Investigational
Anthrax immune globulin humanEstrone may increase the thrombogenic activities of Anthrax immune globulin human.Approved
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Estrone.Approved
Antithrombin III humanEstrone may decrease the anticoagulant activities of Antithrombin III human.Approved
ApixabanEstrone may decrease the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Estrone.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Estrone.Approved, Investigational
AprepitantThe serum concentration of Estrone can be increased when it is combined with Aprepitant.Approved, Investigational
ArdeparinEstrone may decrease the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanEstrone may decrease the anticoagulant activities of Argatroban.Approved, Investigational
AtamestaneThe serum concentration of Atamestane can be increased when it is combined with Estrone.Investigational
AtazanavirThe metabolism of Estrone can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Estrone can be decreased when combined with Atomoxetine.Approved
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Estrone.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Estrone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Estrone.Approved
AzithromycinThe metabolism of Estrone can be decreased when combined with Azithromycin.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Estrone.Approved, Investigational
BCG vaccineThe risk or severity of adverse effects can be increased when Estrone is combined with BCG vaccine.Investigational
BecaplerminEstrone may decrease the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Estrone.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Estrone.Experimental
BendroflumethiazideEstrone may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Estrone.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Estrone.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Estrone.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Estrone.Approved
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Estrone.Approved, Vet Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Estrone.Experimental
Bismuth SubcitrateThe bioavailability of Estrone can be decreased when combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe bioavailability of Estrone can be decreased when combined with Bismuth subnitrate.Experimental
BivalirudinEstrone may decrease the anticoagulant activities of Bivalirudin.Approved, Investigational
BoceprevirThe metabolism of Estrone can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Estrone can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Estrone can be decreased when it is combined with Bosentan.Approved, Investigational
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Estrone.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Estrone.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Estrone.Investigational
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Estrone.Approved
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Estrone.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Estrone.Experimental
BumetanideEstrone may increase the hypokalemic activities of Bumetanide.Approved
CaffeineThe metabolism of Estrone can be decreased when combined with Caffeine.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Estrone.Approved, Nutraceutical
Calcium CarbonateThe bioavailability of Estrone can be decreased when combined with Calcium Carbonate.Approved
Calcium silicateThe bioavailability of Estrone can be decreased when combined with Calcium silicate.Experimental
CapecitabineThe metabolism of Estrone can be decreased when combined with Capecitabine.Approved, Investigational
Capromab pendetideEstrone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CarbamazepineThe metabolism of Estrone can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Estrone.Experimental, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Estrone.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Estrone.Experimental
CelecoxibCelecoxib may increase the thrombogenic activities of Estrone.Approved, Investigational
CeritinibThe serum concentration of Estrone can be increased when it is combined with Ceritinib.Approved
CertoparinEstrone may decrease the anticoagulant activities of Certoparin.Approved, Investigational
Chenodeoxycholic acidThe therapeutic efficacy of Chenodeoxycholic acid can be decreased when used in combination with Estrone.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Estrone.Approved, Vet Approved
ChlorothiazideEstrone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Estrone can be increased when it is combined with Chlorotrianisene.Investigational, Withdrawn
ChlorthalidoneEstrone may increase the hypokalemic activities of Chlorthalidone.Approved
CholecalciferolThe metabolism of Estrone can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Estrone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Estrone.Approved
CiclesonideThe serum concentration of Ciclesonide can be increased when it is combined with Estrone.Approved, Investigational
CinoxacinThe risk or severity of adverse effects can be increased when Estrone is combined with Cinoxacin.Approved, Investigational, Withdrawn
CitalopramThe metabolism of Estrone can be decreased when combined with Citalopram.Approved
Citric AcidEstrone may decrease the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClarithromycinThe metabolism of Estrone can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Estrone can be decreased when combined with Clemastine.Approved
ClobetasolThe serum concentration of Clobetasol can be increased when it is combined with Estrone.Investigational
Clobetasol propionateThe serum concentration of Clobetasol propionate can be increased when it is combined with Estrone.Approved
ClobetasoneThe serum concentration of Clobetasone can be increased when it is combined with Estrone.Approved
ClocortoloneThe serum concentration of Clocortolone can be increased when it is combined with Estrone.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Estrone.Approved
ClopidogrelThe metabolism of Estrone can be decreased when combined with Clopidogrel.Approved, Nutraceutical
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Estrone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
ClotrimazoleThe metabolism of Estrone can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Estrone can be decreased when combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Estrone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Estrone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conestat alfaEstrone may increase the thrombogenic activities of Conestat alfa.Approved
ConivaptanThe serum concentration of Estrone can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated estrogensThe serum concentration of Estrone can be increased when it is combined with Conjugated estrogens.Approved
Cortexolone 17α-propionateThe serum concentration of Cortexolone 17α-propionate can be increased when it is combined with Estrone.Investigational
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Estrone.Approved
CorticosteroneThe serum concentration of Corticosterone can be increased when it is combined with Estrone.Experimental
Cortisone acetateThe serum concentration of Cortisone acetate can be increased when it is combined with Estrone.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Estrone is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CoumaphosThe risk or severity of adverse effects can be increased when Estrone is combined with Coumaphos.Vet Approved
CrisaboroleThe metabolism of Estrone can be decreased when combined with Crisaborole.Approved
CrizotinibThe metabolism of Estrone can be decreased when combined with Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Estrone.Investigational
CyclopenthiazideEstrone may increase the hypokalemic activities of Cyclopenthiazide.Experimental
CyclosporineThe metabolism of Estrone can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Estrone can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Estrone.Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Estrone.Approved
DabrafenibThe serum concentration of Estrone can be decreased when it is combined with Dabrafenib.Approved
DaidzeinThe serum concentration of Estrone can be increased when it is combined with Daidzein.Experimental
DalteparinEstrone may decrease the anticoagulant activities of Dalteparin.Approved
DanaparoidEstrone may decrease the anticoagulant activities of Danaparoid.Approved, Withdrawn
DanazolEstrone may increase the fluid retaining activities of Danazol.Approved
DarexabanEstrone may decrease the anticoagulant activities of Darexaban.Investigational
DarunavirThe metabolism of Estrone can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Estrone can be increased when it is combined with Dasatinib.Approved, Investigational
DecamethoniumThe risk or severity of adverse effects can be increased when Estrone is combined with Decamethonium.Approved
DeferasiroxThe serum concentration of Estrone can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe serum concentration of Deflazacort can be increased when it is combined with Estrone.Approved
DelavirdineThe metabolism of Estrone can be decreased when combined with Delavirdine.Approved
DemecariumThe risk or severity of adverse effects can be increased when Estrone is combined with Demecarium.Approved
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Estrone.Investigational
DesipramineThe metabolism of Estrone can be decreased when combined with Desipramine.Approved
DesirudinEstrone may decrease the anticoagulant activities of Desirudin.Approved
DesonideThe serum concentration of Desonide can be increased when it is combined with Estrone.Approved, Investigational
DesoximetasoneThe serum concentration of Desoximetasone can be increased when it is combined with Estrone.Approved
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Estrone.Approved
Desoxycorticosterone PivalateThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Estrone.Experimental, Vet Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Estrone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Estrone.Vet Approved
DextranEstrone may decrease the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Estrone may decrease the anticoagulant activities of Dextran 40.Approved
Dextran 70Estrone may decrease the anticoagulant activities of Dextran 70.Approved
Dextran 75Estrone may decrease the anticoagulant activities of Dextran 75.Approved
DichlorvosThe risk or severity of adverse effects can be increased when Estrone is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Estrone.Approved, Vet Approved
DicoumarolEstrone may decrease the anticoagulant activities of Dicoumarol.Approved
DienestrolThe serum concentration of Estrone can be increased when it is combined with Dienestrol.Approved, Investigational
DiethylstilbestrolThe serum concentration of Estrone can be increased when it is combined with Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Estrone.Experimental
DiflorasoneThe serum concentration of Diflorasone can be increased when it is combined with Estrone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Estrone.Approved
DifluocortoloneThe serum concentration of Difluocortolone can be increased when it is combined with Estrone.Approved, Investigational
DifluprednateThe serum concentration of Difluprednate can be increased when it is combined with Estrone.Approved
DihydroergotamineThe metabolism of Estrone can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneEstrone may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DiltiazemThe metabolism of Estrone can be decreased when combined with Diltiazem.Approved
DistigmineThe risk or severity of adverse effects can be increased when Estrone is combined with Distigmine.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Estrone is combined with Donepezil.Approved
DosulepinThe metabolism of Estrone can be decreased when combined with Dosulepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Estrone.Approved, Investigational
DoxorubicinThe metabolism of Estrone can be decreased when combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Estrone can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Estrone can be decreased when combined with Dronedarone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Estrone.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Estrone.Investigational
DyphyllineThe serum concentration of Dyphylline can be increased when it is combined with Estrone.Approved
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Estrone.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Estrone is combined with Echothiophate.Approved
Edetic AcidEstrone may decrease the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanEstrone may decrease the anticoagulant activities of Edoxaban.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Estrone is combined with Edrophonium.Approved
EfavirenzThe metabolism of Estrone can be decreased when combined with Efavirenz.Approved, Investigational
EnoxacinThe risk or severity of adverse effects can be increased when Estrone is combined with Enoxacin.Approved, Investigational
EnoxaparinEstrone may decrease the anticoagulant activities of Enoxaparin.Approved
EnzalutamideThe serum concentration of Estrone can be decreased when it is combined with Enzalutamide.Approved
EpimestrolThe serum concentration of Estrone can be increased when it is combined with Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Estrone.Approved
EquileninThe serum concentration of Equilenin can be increased when it is combined with Estrone.Experimental
EquilinThe serum concentration of Equilin can be increased when it is combined with Estrone.Approved
EquolThe serum concentration of Estrone can be increased when it is combined with Equol.Investigational
ErythromycinThe metabolism of Estrone can be decreased when combined with Erythromycin.Approved, Vet Approved
EstradiolThe serum concentration of Estrone can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estrone can be increased when it is combined with Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedThe serum concentration of Estrone can be increased when it is combined with Estrogens, esterified.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be increased when it is combined with Estrone.Approved
Etacrynic acidEstrone may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Estrone.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Estrone.Experimental
Ethinyl EstradiolThe serum concentration of Estrone can be increased when it is combined with Ethinyl Estradiol.Approved
Ethyl biscoumacetateEstrone may decrease the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacEtodolac may increase the thrombogenic activities of Estrone.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Estrone.Approved, Investigational
EtoricoxibEtoricoxib may increase the thrombogenic activities of Estrone.Approved, Investigational
EtravirineThe metabolism of Estrone can be decreased when combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Estrone.Approved, Investigational
ExemestaneThe therapeutic efficacy of Exemestane can be decreased when used in combination with Estrone.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Estrone.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Estrone.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Estrone.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Estrone.Approved
FenthionThe risk or severity of adverse effects can be increased when Estrone is combined with Fenthion.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Estrone.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Estrone.Experimental
Ferulic acidEstrone may decrease the anticoagulant activities of Ferulic acid.Experimental
FleroxacinThe risk or severity of adverse effects can be increased when Estrone is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Estrone.Approved, Withdrawn
FloxuridineThe metabolism of Estrone can be decreased when combined with Floxuridine.Approved
fluasteroneThe serum concentration of fluasterone can be increased when it is combined with Estrone.Investigational
FluconazoleThe metabolism of Estrone can be decreased when combined with Fluconazole.Approved
FludrocortisoneThe serum concentration of Fludrocortisone can be increased when it is combined with Estrone.Approved
FluindioneEstrone may decrease the anticoagulant activities of Fluindione.Investigational
FlumequineThe risk or severity of adverse effects can be increased when Estrone is combined with Flumequine.Withdrawn
FlumethasoneThe serum concentration of Flumethasone can be increased when it is combined with Estrone.Approved, Vet Approved
FlunisolideThe serum concentration of Flunisolide can be increased when it is combined with Estrone.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Estrone.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Estrone.Experimental
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Estrone.Approved, Investigational, Vet Approved
FluocinonideThe serum concentration of Fluocinonide can be increased when it is combined with Estrone.Approved, Investigational
FluocortoloneThe serum concentration of Fluocortolone can be increased when it is combined with Estrone.Approved, Withdrawn
FluorometholoneThe serum concentration of Fluorometholone can be increased when it is combined with Estrone.Approved
FluorouracilThe metabolism of Estrone can be decreased when combined with Fluorouracil.Approved
FluoxymesteroneEstrone may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FluprednideneThe serum concentration of Fluprednidene can be increased when it is combined with Estrone.Approved, Withdrawn
FluprednisoloneThe serum concentration of Fluprednisolone can be increased when it is combined with Estrone.Approved
FlurandrenolideThe serum concentration of Flurandrenolide can be increased when it is combined with Estrone.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Estrone.Approved, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Estrone.Approved
Fluticasone propionateThe serum concentration of Fluticasone propionate can be increased when it is combined with Estrone.Approved
FluvastatinThe metabolism of Estrone can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Estrone can be decreased when combined with Fluvoxamine.Approved, Investigational
FondaparinuxEstrone may decrease the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumEstrone may decrease the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
FormestaneThe serum concentration of Formestane can be increased when it is combined with Estrone.Approved, Investigational, Withdrawn
FosamprenavirThe metabolism of Estrone can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Estrone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Estrone can be increased when combined with Fosphenytoin.Approved
FurosemideEstrone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Estrone can be increased when it is combined with Fusidic Acid.Approved
G17DTThe risk or severity of adverse effects can be increased when Estrone is combined with G17DT.Investigational
GabexateEstrone may decrease the anticoagulant activities of Gabexate.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Estrone is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Estrone is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Estrone is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Estrone is combined with Gatifloxacin.Approved, Investigational
GemfibrozilThe metabolism of Estrone can be decreased when combined with Gemfibrozil.Approved
GemifloxacinThe risk or severity of adverse effects can be increased when Estrone is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Estrone can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Estrone is combined with GI-5005.Investigational
GLPG-0492Estrone may increase the fluid retaining activities of GLPG-0492.Investigational
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Estrone.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Estrone is combined with Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Estrone.Experimental
HalcinonideThe serum concentration of Halcinonide can be increased when it is combined with Estrone.Approved, Investigational, Withdrawn
HE3286The serum concentration of HE3286 can be increased when it is combined with Estrone.Investigational
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Estrone.Experimental
HeparinEstrone may decrease the anticoagulant activities of Heparin.Approved, Investigational
Hepatitis A VaccineThe risk or severity of adverse effects can be increased when Estrone is combined with Hepatitis A Vaccine.Approved
Hepatitis B Vaccine (Recombinant)The risk or severity of adverse effects can be increased when Estrone is combined with Hepatitis B Vaccine (Recombinant).Approved, Withdrawn
HexestrolThe serum concentration of Estrone can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Estrone.Investigational
Human C1-esterase inhibitorEstrone may increase the thrombogenic activities of Human C1-esterase inhibitor.Approved
Huperzine AThe risk or severity of adverse effects can be increased when Estrone is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Estrone.Approved, Investigational
HydrochlorothiazideEstrone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Estrone.Approved, Vet Approved
HydroflumethiazideEstrone may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational
HydrotalciteThe bioavailability of Estrone can be decreased when combined with Hydrotalcite.Experimental, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Estrone.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Estrone.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Estrone.Approved
IdelalisibThe serum concentration of Estrone can be increased when it is combined with Idelalisib.Approved
IdraparinuxEstrone may decrease the anticoagulant activities of Idraparinux.Investigational
ImatinibThe metabolism of Estrone can be decreased when combined with Imatinib.Approved
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Estrone.Experimental
IndacaterolIndacaterol may increase the hypokalemic activities of Estrone.Approved
IndapamideEstrone may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe metabolism of Estrone can be decreased when combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Estrone.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Estrone.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Estrone.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Estrone is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Estrone is combined with INGN 225.Investigational
IpidacrineThe risk or severity of adverse effects can be increased when Estrone is combined with Ipidacrine.Experimental
IrbesartanThe metabolism of Estrone can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Estrone can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoflurophateThe risk or severity of adverse effects can be increased when Estrone is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Estrone.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Estrone.Withdrawn
IsradipineThe metabolism of Estrone can be decreased when combined with Isradipine.Approved
IstaroximeThe serum concentration of Istaroxime can be increased when it is combined with Estrone.Investigational
ItraconazoleThe metabolism of Estrone can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Estrone can be increased when it is combined with Ivacaftor.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Estrone.Experimental
KetoconazoleThe metabolism of Estrone can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Estrone.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Estrone.Approved
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Estrone.Approved
LeflunomideThe metabolism of Estrone can be decreased when combined with Leflunomide.Approved, Investigational
LenalidomideEstrone may increase the thrombogenic activities of Lenalidomide.Approved
LepirudinEstrone may decrease the anticoagulant activities of Lepirudin.Approved
LetaxabanEstrone may decrease the anticoagulant activities of Letaxaban.Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Estrone is combined with Levofloxacin.Approved, Investigational
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Estrone.Approved
LidocaineThe metabolism of Estrone can be decreased when combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Estrone.Approved
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Estrone.Approved, Vet Approved
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Estrone.Approved
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Estrone.Investigational
LobeglitazoneThe metabolism of Estrone can be decreased when combined with Lobeglitazone.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Estrone.Experimental
LopinavirThe metabolism of Estrone can be decreased when combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Estrone.Approved, Investigational
LosartanThe metabolism of Estrone can be decreased when combined with Losartan.Approved
LoteprednolThe serum concentration of Loteprednol can be increased when it is combined with Estrone.Approved
LovastatinThe metabolism of Estrone can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Estrone.Approved, Investigational
LuliconazoleThe serum concentration of Estrone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Estrone can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibLumiracoxib may increase the thrombogenic activities of Estrone.Approved, Investigational
MagaldrateThe bioavailability of Estrone can be decreased when combined with Magaldrate.Approved, Withdrawn
Magnesium HydroxideThe bioavailability of Estrone can be decreased when combined with Magnesium Hydroxide.Approved
Magnesium oxideThe bioavailability of Estrone can be decreased when combined with Magnesium oxide.Approved
Magnesium peroxideThe bioavailability of Estrone can be decreased when combined with Magnesium peroxide.Experimental
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Estrone.Approved
Magnesium silicateThe bioavailability of Estrone can be decreased when combined with Magnesium silicate.Approved, Experimental
Magnesium TrisilicateThe bioavailability of Estrone can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Estrone is combined with Malathion.Approved, Investigational
ManidipineThe metabolism of Estrone can be decreased when combined with Manidipine.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Estrone.Approved, Investigational
ME-609The serum concentration of ME-609 can be increased when it is combined with Estrone.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Estrone.Approved, Vet Approved
MedrysoneThe serum concentration of Medrysone can be increased when it is combined with Estrone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Estrone.Approved
MefloquineThe risk or severity of adverse effects can be increased when Estrone is combined with Mefloquine.Approved
MelagatranEstrone may decrease the anticoagulant activities of Melagatran.Experimental
MelengestrolThe serum concentration of Melengestrol can be increased when it is combined with Estrone.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Estrone.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Estrone is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Estrone.Approved
MesteroloneEstrone may increase the fluid retaining activities of Mesterolone.Experimental
MestranolThe serum concentration of Estrone can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Estrone.Investigational, Withdrawn
MethallenestrilThe serum concentration of Estrone can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Estrone is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazideEstrone may increase the hypokalemic activities of Methyclothiazide.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Estrone.Approved, Vet Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Estrone.Approved, Vet Approved
MethyltestosteroneEstrone may increase the fluid retaining activities of Methyltestosterone.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Estrone is combined with Metoclopramide.Approved, Investigational
MetolazoneEstrone may increase the hypokalemic activities of Metolazone.Approved
MexiletineThe metabolism of Estrone can be decreased when combined with Mexiletine.Approved
MidostaurinThe metabolism of Estrone can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Estrone can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Estrone is combined with Minaprine.Approved
MitotaneThe serum concentration of Estrone can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Estrone.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Estrone.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Estrone.Experimental
MometasoneThe serum concentration of Mometasone can be increased when it is combined with Estrone.Approved, Vet Approved
MoxestrolThe serum concentration of Estrone can be increased when it is combined with Moxestrol.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Estrone.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Estrone.Approved
NabumetoneNabumetone may increase the thrombogenic activities of Estrone.Approved
NadroparinEstrone may decrease the anticoagulant activities of Nadroparin.Approved
NafamostatEstrone may decrease the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Estrone.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Estrone is combined with Nalidixic Acid.Approved, Investigational
NandroloneEstrone may increase the fluid retaining activities of Nandrolone.Experimental, Investigational
Nandrolone decanoateEstrone may increase the fluid retaining activities of Nandrolone decanoate.Approved, Illicit
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Estrone.Approved, Vet Approved
NCX 1022The serum concentration of NCX 1022 can be increased when it is combined with Estrone.Investigational
NefazodoneThe metabolism of Estrone can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Estrone can be decreased when combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Estrone is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when Estrone is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Estrone.Approved
NetupitantThe serum concentration of Estrone can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Estrone can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Estrone can be decreased when combined with Nicardipine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Estrone is combined with Nicorandil.Approved, Investigational
NicotineThe metabolism of Estrone can be decreased when combined with Nicotine.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Estrone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Estrone.Approved
NilotinibThe metabolism of Estrone can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Estrone.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Estrone.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Estrone is combined with Norfloxacin.Approved
OlaparibThe metabolism of Estrone can be decreased when combined with Olaparib.Approved
Oleoyl-estroneThe serum concentration of Oleoyl-estrone can be increased when it is combined with Estrone.Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Estrone.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Estrone.Approved
OmeprazoleThe metabolism of Estrone can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Estrone.Vet Approved
OsimertinibThe serum concentration of Estrone can be increased when it is combined with Osimertinib.Approved
OspemifeneThe risk or severity of adverse effects can be increased when Estrone is combined with Ospemifene.Approved
OtamixabanEstrone may decrease the anticoagulant activities of Otamixaban.Investigational
OxandroloneEstrone may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Estrone.Approved
Oxolinic acidThe risk or severity of adverse effects can be increased when Estrone is combined with Oxolinic acid.Experimental
OxymetholoneEstrone may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Estrone.Approved, Withdrawn
PalbociclibThe serum concentration of Estrone can be increased when it is combined with Palbociclib.Approved
ParamethasoneThe serum concentration of Paramethasone can be increased when it is combined with Estrone.Approved
ParaoxonThe risk or severity of adverse effects can be increased when Estrone is combined with Paraoxon.Experimental
ParecoxibParecoxib may increase the thrombogenic activities of Estrone.Approved
ParoxetineThe metabolism of Estrone can be decreased when combined with Paroxetine.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Estrone.Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Estrone.Approved
PazufloxacinThe risk or severity of adverse effects can be increased when Estrone is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Estrone is combined with Pefloxacin.Approved
Peginterferon alfa-2bThe serum concentration of Estrone can be increased when it is combined with Peginterferon alfa-2b.Approved
Pentaerythritol TetranitrateEstrone may decrease the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
PentobarbitalThe metabolism of Estrone can be increased when combined with Pentobarbital.Approved, Vet Approved
Pentosan PolysulfateEstrone may decrease the anticoagulant activities of Pentosan Polysulfate.Approved
PhenindioneEstrone may decrease the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe metabolism of Estrone can be increased when combined with Phenobarbital.Approved
PhenprocoumonEstrone may decrease the anticoagulant activities of Phenprocoumon.Approved, Investigational
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Estrone.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Estrone.Approved, Vet Approved
Phenylbutyric acidThe therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Estrone.Approved, Investigational
PhenytoinThe metabolism of Estrone can be increased when combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Estrone is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Estrone.Approved, Investigational
Pipemidic acidThe risk or severity of adverse effects can be increased when Estrone is combined with Pipemidic acid.Experimental
PiretanideEstrone may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Estrone.Approved, Investigational
Piromidic acidThe risk or severity of adverse effects can be increased when Estrone is combined with Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Estrone.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Estrone.Experimental
Polyestradiol phosphateThe serum concentration of Estrone can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazideEstrone may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe metabolism of Estrone can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Estrone.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Estrone.Approved, Nutraceutical
Prasterone sulfateThe serum concentration of Prasterone sulfate can be increased when it is combined with Estrone.Investigational
PrednicarbateThe serum concentration of Prednicarbate can be increased when it is combined with Estrone.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Estrone.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Estrone.Approved, Vet Approved
PregnenoloneThe serum concentration of Pregnenolone can be increased when it is combined with Estrone.Experimental, Investigational
PrimidoneThe metabolism of Estrone can be increased when combined with Primidone.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Estrone.Experimental
PromestrieneThe serum concentration of Estrone can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Estrone.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Estrone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Estrone.Experimental
Protein CEstrone may decrease the anticoagulant activities of Protein C.Approved
Protein S humanEstrone may decrease the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeEstrone may decrease the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinThe risk or severity of adverse effects can be increased when Estrone is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Estrone.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Estrone is combined with Pyridostigmine.Approved
PyrimethamineThe metabolism of Estrone can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe serum concentration of Estrone can be increased when it is combined with Quazepam.Approved, Illicit
QuinestrolThe serum concentration of Estrone can be increased when it is combined with Quinestrol.Approved
QuinethazoneEstrone may increase the hypokalemic activities of Quinethazone.Approved
QuinineThe metabolism of Estrone can be decreased when combined with Quinine.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Estrone is combined with Rabies virus inactivated antigen, A.Approved
RanolazineThe serum concentration of Estrone can be increased when it is combined with Ranolazine.Approved, Investigational
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Estrone.Withdrawn
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Estrone.Approved, Experimental, Investigational
ReviparinEstrone may decrease the anticoagulant activities of Reviparin.Approved, Investigational
RifabutinThe metabolism of Estrone can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Estrone can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Estrone can be increased when combined with Rifapentine.Approved
RimexoloneThe serum concentration of Rimexolone can be increased when it is combined with Estrone.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Estrone is combined with Rindopepimut.Investigational
RivaroxabanEstrone may decrease the anticoagulant activities of Rivaroxaban.Approved
RivastigmineThe risk or severity of adverse effects can be increased when Estrone is combined with Rivastigmine.Approved, Investigational
RofecoxibRofecoxib may increase the thrombogenic activities of Estrone.Investigational, Withdrawn
RopiniroleThe serum concentration of Ropinirole can be increased when it is combined with Estrone.Approved, Investigational
RosoxacinThe risk or severity of adverse effects can be increased when Estrone is combined with Rosoxacin.Approved, Investigational
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Estrone is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Estrone is combined with Rubella virus vaccine.Approved
RufloxacinThe risk or severity of adverse effects can be increased when Estrone is combined with Rufloxacin.Experimental
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Estrone.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Estrone.Approved, Vet Approved
Salmonella typhi ty21a live antigenThe risk or severity of adverse effects can be increased when Estrone is combined with Salmonella typhi ty21a live antigen.Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Estrone.Approved
SaquinavirThe metabolism of Estrone can be decreased when combined with Saquinavir.Approved, Investigational
SecobarbitalThe metabolism of Estrone can be increased when combined with Secobarbital.Approved, Vet Approved
SecoisolariciresinolThe serum concentration of Estrone can be increased when it is combined with Secoisolariciresinol.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Estrone.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Estrone.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Estrone.Investigational
SertralineThe metabolism of Estrone can be decreased when combined with Sertraline.Approved
SildenafilThe metabolism of Estrone can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Estrone can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Estrone can be increased when it is combined with Simeprevir.Approved
SitafloxacinThe risk or severity of adverse effects can be increased when Estrone is combined with Sitafloxacin.Experimental, Investigational
Sodium bicarbonateThe bioavailability of Estrone can be decreased when combined with Sodium bicarbonate.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Estrone.Approved
SomatotropinThe therapeutic efficacy of Somatotropin can be decreased when used in combination with Estrone.Approved, Investigational
SorafenibThe metabolism of Estrone can be decreased when combined with Sorafenib.Approved, Investigational
SparfloxacinThe risk or severity of adverse effects can be increased when Estrone is combined with Sparfloxacin.Approved, Investigational
SRP 299The risk or severity of adverse effects can be increased when Estrone is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Estrone.Investigational
St. John's WortThe serum concentration of Estrone can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StanozololEstrone may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StiripentolThe serum concentration of Estrone can be increased when it is combined with Stiripentol.Approved
SulfadiazineThe metabolism of Estrone can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Estrone can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Estrone.Approved
SulfisoxazoleThe metabolism of Estrone can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Estrone.Approved
SulodexideEstrone may decrease the anticoagulant activities of Sulodexide.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Estrone.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Estrone.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Estrone can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Estrone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Estrone is combined with Tacrine.Investigational, Withdrawn
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Estrone.Investigational
TecemotideThe risk or severity of adverse effects can be increased when Estrone is combined with Tecemotide.Investigational
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Estrone.Approved, Withdrawn
TelithromycinThe metabolism of Estrone can be decreased when combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Estrone is combined with Temafloxacin.Withdrawn
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Estrone.Experimental
Tenofovir disoproxilThe metabolism of Estrone can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Estrone.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Estrone.Vet Approved
TeriflunomideThe serum concentration of Estrone can be decreased when it is combined with Teriflunomide.Approved
TestosteroneEstrone may increase the fluid retaining activities of Testosterone.Approved, Investigational
Testosterone PropionateEstrone may increase the fluid retaining activities of Testosterone Propionate.Approved, Vet Approved
TG4010The risk or severity of adverse effects can be increased when Estrone is combined with TG4010.Investigational
ThalidomideEstrone may increase the thrombogenic activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Estrone can be decreased when combined with Theophylline.Approved
ThiotepaThe metabolism of Estrone can be decreased when combined with Thiotepa.Approved
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Estrone.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Estrone.Approved
TiboloneThe serum concentration of Estrone can be increased when it is combined with Tibolone.Approved, Investigational
TicagrelorThe metabolism of Estrone can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Estrone can be decreased when combined with Ticlopidine.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Estrone.Investigational
TipranavirEstrone may increase the dermatologic adverse activities of Tipranavir.Approved, Investigational
TixocortolThe serum concentration of Tixocortol can be increased when it is combined with Estrone.Approved
TocilizumabThe serum concentration of Estrone can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Estrone can be decreased when combined with Tolbutamide.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Estrone.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Estrone.Approved
TopiroxostatThe metabolism of Estrone can be decreased when combined with Topiroxostat.Approved, Investigational
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Estrone.Approved, Investigational
TorasemideEstrone may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Estrone.Approved, Investigational
TriamcinoloneThe serum concentration of Triamcinolone can be increased when it is combined with Estrone.Approved, Vet Approved
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Estrone.Experimental
TrichlorfonThe risk or severity of adverse effects can be increased when Estrone is combined with Trichlorfon.Vet Approved
TrichlormethiazideEstrone may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TrimethoprimThe metabolism of Estrone can be decreased when combined with Trimethoprim.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Estrone.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Estrone.Approved
TromethamineThe bioavailability of Estrone can be decreased when combined with Tromethamine.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when Estrone is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinEstrone may decrease the anticoagulant activities of Troxerutin.Investigational
TubocurarineThe risk or severity of adverse effects can be increased when Estrone is combined with Tubocurarine.Approved
UlobetasolThe serum concentration of Ulobetasol can be increased when it is combined with Estrone.Approved
Ursodeoxycholic acidThe therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Estrone.Approved, Investigational
ValdecoxibValdecoxib may increase the thrombogenic activities of Estrone.Investigational, Withdrawn
Valproic AcidThe metabolism of Estrone can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Estrone can be decreased when combined with Valsartan.Approved, Investigational
VemurafenibThe serum concentration of Estrone can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Estrone can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Estrone can be decreased when combined with Verapamil.Approved
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Estrone.Approved, Investigational
Vitamin CThe serum concentration of Estrone can be increased when it is combined with Vitamin C.Approved, Nutraceutical
VoriconazoleThe metabolism of Estrone can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinEstrone may increase the anticoagulant activities of Warfarin.Approved
XimelagatranEstrone may decrease the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Yellow fever vaccineThe risk or severity of adverse effects can be increased when Estrone is combined with Yellow fever vaccine.Approved
ZafirlukastThe metabolism of Estrone can be decreased when combined with Zafirlukast.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Estrone.Approved, Investigational
ZeranolThe serum concentration of Estrone can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Estrone.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Estrone can be decreased when combined with Ziprasidone.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Estrone.Withdrawn
Zoster vaccineThe risk or severity of adverse effects can be increased when Estrone is combined with Zoster vaccine.Approved
ZucapsaicinThe metabolism of Estrone can be decreased when combined with Zucapsaicin.Approved
Food Interactions
Not Available

References

Synthesis Reference

Seiichi Takano, Kunio Ogasawara, "Method for producing (+)-estrone derivatives." U.S. Patent US5424462, issued January, 1965.

US5424462
General References
  1. Miyoshi Y, Tanji Y, Taguchi T, Tamaki Y, Noguchi S: Association of serum estrone levels with estrogen receptor-positive breast cancer risk in postmenopausal Japanese women. Clin Cancer Res. 2003 Jun;9(6):2229-33. [PubMed:12796390]
  2. Kajta M, Lason W, Bien E, Marszal M: Neuroprotective effects of estrone on NMDA-induced toxicity in primary cultures of rat cortical neurons are independent of estrogen receptors. Pol J Pharmacol. 2002 Nov-Dec;54(6):727-9. [PubMed:12866733]
External Links
Human Metabolome Database
HMDB00145
KEGG Drug
D00067
KEGG Compound
C00468
PubChem Compound
5870
PubChem Substance
46505916
ChemSpider
5660
BindingDB
17289
ChEBI
17263
ChEMBL
CHEMBL1405
Therapeutic Targets Database
DAP001020
PharmGKB
PA449512
IUPHAR
2818
Guide to Pharmacology
GtP Drug Page
HET
J3Z
Wikipedia
Estrone
ATC Codes
G03CA07 — EstroneG03CC04 — Estrone
AHFS Codes
  • 68:16.04 — Estrogens
PDB Entries
3hm1 / 5hs6
MSDS
Download (76.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Unknown StatusDiagnosticPremenstrual Syndrome1
2Unknown StatusTreatmentPremenstrual Syndrome1

Pharmacoeconomics

Manufacturers
  • Wyeth ayerst laboratories
  • Watson laboratories inc
  • Parkedale pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
CreamVaginal0.1 %
SuppositoryVaginal.25 mg
CreamVaginal1 mg
Prices
Unit descriptionCostUnit
Estrone powder21.42USD g
Estrone crystal11.76USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)260.2 °CPhysProp
boiling point (°C)154 °CPhysProp
water solubility30 mg/L (at 25 °C)MERCK INDEX (1996)
logP3.13HANSCH,C ET AL. (1995)
logS-3.96ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.00394 mg/mLALOGPS
logP4.03ALOGPS
logP4.31ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)10.33ChemAxon
pKa (Strongest Basic)-5.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area37.3 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity79.08 m3·mol-1ChemAxon
Polarizability31.27 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9529
Caco-2 permeable+0.8934
P-glycoprotein substrateSubstrate0.6001
P-glycoprotein inhibitor INon-inhibitor0.9066
P-glycoprotein inhibitor IINon-inhibitor0.8882
Renal organic cation transporterNon-inhibitor0.73
CYP450 2C9 substrateNon-substrate0.6624
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.729
CYP450 1A2 substrateInhibitor0.9017
CYP450 2C9 inhibitorNon-inhibitor0.9353
CYP450 2D6 inhibitorNon-inhibitor0.9599
CYP450 2C19 inhibitorNon-inhibitor0.8954
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8681
Ames testNon AMES toxic0.9268
CarcinogenicityNon-carcinogens0.8917
BiodegradationNot ready biodegradable0.9717
Rat acute toxicity1.9267 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8711
hERG inhibition (predictor II)Inhibitor0.5459
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (9.95 KB)
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-MS (1 TMS)GC-MSsplash10-05ox-3951000000-8bc438f505b3cf49b21f
GC-MS Spectrum - GC-MS (1 MEOX; 1 TMS)GC-MSsplash10-003u-4942000000-a72ea34d85d9d524c247
GC-MS Spectrum - GC-MS (1 MEOX; 1 TMS)GC-MSsplash10-0019-8931000000-aad9803af812c7c40f53
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-00di-2940000000-2d417e7ecb4a8b87b817
GC-MS Spectrum - EI-BGC-MSsplash10-00di-0980000000-5b293db89a0f2efeb784
GC-MS Spectrum - GC-MSGC-MSsplash10-05ox-3951000000-8bc438f505b3cf49b21f
GC-MS Spectrum - GC-MSGC-MSsplash10-003u-4942000000-a72ea34d85d9d524c247
GC-MS Spectrum - GC-MSGC-MSsplash10-0019-8931000000-aad9803af812c7c40f53
Mass Spectrum (Electron Ionization)MSsplash10-00di-2930000000-c99df908474247066a2b
MS/MS Spectrum - Quattro_QQQ 10V, PositiveLC-MS/MSsplash10-00di-0190000000-071e67516e11357ff64e
MS/MS Spectrum - Quattro_QQQ 25V, PositiveLC-MS/MSsplash10-0a4j-4910000000-20e059a7c508ba492af3
MS/MS Spectrum - Quattro_QQQ 40V, PositiveLC-MS/MSsplash10-067i-9700000000-9ff5214f08822f238fa9
MS/MS Spectrum - EI-B (HITACHI M-80) , PositiveLC-MS/MSsplash10-00di-2940000000-3b9744c27d6a3d2eff6e
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-014i-0690000000-a76244de959b06ec896e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a59-0910000000-4a1bc1cbc90c3e5281e6
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a59-0900000000-0830d4ad43804976f508
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0390000000-41440e74b3f0b5f365d7
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0390000000-fdc0255246e3a9013d0a
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a59-2910000000-fc5173d435c3c7fc603c
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00di-0390000000-25cecb1c4785e7bffd56
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as estrogens and derivatives. These are steroids with a structure containing a 3-hydroxylated estrane.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Estrane steroids
Direct Parent
Estrogens and derivatives
Alternative Parents
3-hydroxysteroids / 17-oxosteroids / Phenanthrenes and derivatives / Tetralins / 1-hydroxy-2-unsubstituted benzenoids / Ketones / Organic oxides / Hydrocarbon derivatives
Substituents
Estrogen-skeleton / 3-hydroxysteroid / Hydroxysteroid / 17-oxosteroid / Oxosteroid / Phenanthrene / Tetralin / 1-hydroxy-2-unsubstituted benzenoid / Benzenoid / Ketone
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
17-oxo steroid, 3-hydroxy steroid (CHEBI:17263) / estrane, C18 steroids (estrogens) and derivatives, Estrane and derivatives, Estrogens (C00468) / C18 steroids (estrogens) and derivatives (LMST02010004)

Targets

Details
1. Estrogen receptor alpha
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissu...
Gene Name
ESR1
Uniprot ID
P03372
Uniprot Name
Estrogen receptor
Molecular Weight
66215.45 Da
References
  1. Margeat E, Bourdoncle A, Margueron R, Poujol N, Cavailles V, Royer C: Ligands differentially modulate the protein interactions of the human estrogen receptors alpha and beta. J Mol Biol. 2003 Feb 7;326(1):77-92. [PubMed:12547192]
  2. Sasson S: Equilibrium binding analysis of estrogen agonists and antagonists: relation to the activation of the estrogen receptor. Pathol Biol (Paris). 1991 Jan;39(1):59-69. [PubMed:2011412]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Details
2. Estrogen receptor beta
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Nuclear hormone receptor. Binds estrogens with an affinity similar to that of ESR1, and activates expression of reporter genes containing estrogen response elements (ERE) in an estrogen-dependent m...
Gene Name
ESR2
Uniprot ID
Q92731
Uniprot Name
Estrogen receptor beta
Molecular Weight
59215.765 Da
References
  1. Gutendorf B, Westendorf J: Comparison of an array of in vitro assays for the assessment of the estrogenic potential of natural and synthetic estrogens, phytoestrogens and xenoestrogens. Toxicology. 2001 Sep 14;166(1-2):79-89. [PubMed:11518614]
  2. Dang Z: Comparison of relative binding affinities to fish and mammalian estrogen receptors: the regulatory implications. Toxicol Lett. 2010 Feb 15;192(3):298-315. doi: 10.1016/j.toxlet.2009.11.004. Epub 2009 Nov 12. [PubMed:19913605]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription ...
Gene Name
AR
Uniprot ID
P10275
Uniprot Name
Androgen receptor
Molecular Weight
98987.9 Da
References
  1. Kojima H, Iida M, Katsura E, Kanetoshi A, Hori Y, Kobayashi K: Effects of a diphenyl ether-type herbicide, chlornitrofen, and its amino derivative on androgen and estrogen receptor activities. Environ Health Perspect. 2003 Apr;111(4):497-502. [PubMed:12676605]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Oxygen binding
Specific Function
Catalyzes the formation of aromatic C18 estrogens from C19 androgens.
Gene Name
CYP19A1
Uniprot ID
P11511
Uniprot Name
Aromatase
Molecular Weight
57882.48 Da
References
  1. Numazawa M, Ando M, Watari Y, Tominaga T, Hayata Y, Yoshimura A: Structure-activity relationships of 2-, 4-, or 6-substituted estrogens as aromatase inhibitors. J Steroid Biochem Mol Biol. 2005 Jun;96(1):51-8. [PubMed:16039845]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Androgen binding
Specific Function
Functions as an androgen transport protein, but may also be involved in receptor mediated processes. Each dimer binds one molecule of steroid. Specific for 5-alpha-dihydrotestosterone, testosterone...
Gene Name
SHBG
Uniprot ID
P04278
Uniprot Name
Sex hormone-binding globulin
Molecular Weight
43778.755 Da
References
  1. Hong H, Branham WS, Ng HW, Moland CL, Dial SL, Fang H, Perkins R, Sheehan D, Tong W: Human sex hormone-binding globulin binding affinities of 125 structurally diverse chemicals and comparison with their binding to androgen receptor, estrogen receptor, and alpha-fetoprotein. Toxicol Sci. 2015 Feb;143(2):333-48. doi: 10.1093/toxsci/kfu231. Epub 2014 Oct 27. [PubMed:25349334]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Lin Y, Lu P, Tang C, Mei Q, Sandig G, Rodrigues AD, Rushmore TH, Shou M: Substrate inhibition kinetics for cytochrome P450-catalyzed reactions. Drug Metab Dispos. 2001 Apr;29(4 Pt 1):368-74. [PubMed:11259318]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Lee AJ, Cai MX, Thomas PE, Conney AH, Zhu BT: Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98. [PubMed:12865317]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1B1
Uniprot ID
Q16678
Uniprot Name
Cytochrome P450 1B1
Molecular Weight
60845.33 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Leukotriene-b4 20-monooxygenase activity
Specific Function
Catalyzes the omega- and (omega-1)-hydroxylation of various fatty acids such as laurate, myristate and palmitate. Has little activity toward prostaglandins A1 and E1. Oxidizes arachidonic acid to 2...
Gene Name
CYP4A11
Uniprot ID
Q02928
Uniprot Name
Cytochrome P450 4A11
Molecular Weight
59347.31 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
No
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Tan E, Lu T, Pang KS: Futile cycling of estrone sulfate and estrone in the recirculating perfused rat liver preparation. J Pharmacol Exp Ther. 2001 Apr;297(1):423-36. [PubMed:11259571]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.
Gene Name
SLCO2B1
Uniprot ID
O94956
Uniprot Name
Solute carrier organic anion transporter family member 2B1
Molecular Weight
76709.98 Da
References
  1. Tamai I, Nozawa T, Koshida M, Nezu J, Sai Y, Tsuji A: Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C. Pharm Res. 2001 Sep;18(9):1262-9. [PubMed:11683238]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Noguchi K, Kawahara H, Kaji A, Katayama K, Mitsuhashi J, Sugimoto Y: Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib. Cancer Sci. 2009 Sep;100(9):1701-7. doi: 10.1111/j.1349-7006.2009.01213.x. Epub 2009 May 12. [PubMed:19493273]
  2. Kim WY, Benet LZ: P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res. 2004 Jul;21(7):1284-93. [PubMed:15290871]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
Gene Name
SLCO1A2
Uniprot ID
P46721
Uniprot Name
Solute carrier organic anion transporter family member 1A2
Molecular Weight
74144.105 Da
References
  1. Kanai N, Lu R, Bao Y, Wolkoff AW, Vore M, Schuster VL: Estradiol 17 beta-D-glucuronide is a high-affinity substrate for oatp organic anion transporter. Am J Physiol. 1996 Feb;270(2 Pt 2):F326-31. [PubMed:8779894]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
References
  1. Imai Y, Tsukahara S, Asada S, Sugimoto Y: Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. Cancer Res. 2004 Jun 15;64(12):4346-52. [PubMed:15205350]
  2. Sugimoto Y, Tsukahara S, Imai Y, Sugimoto Y, Ueda K, Tsuruo T: Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists. Mol Cancer Ther. 2003 Jan;2(1):105-12. [PubMed:12533678]
  3. Suzuki M, Suzuki H, Sugimoto Y, Sugiyama Y: ABCG2 transports sulfated conjugates of steroids and xenobiotics. J Biol Chem. 2003 Jun 20;278(25):22644-9. Epub 2003 Apr 7. [PubMed:12682043]
  4. Imai Y, Asada S, Tsukahara S, Ishikawa E, Tsuruo T, Sugimoto Y: Breast cancer resistance protein exports sulfated estrogens but not free estrogens. Mol Pharmacol. 2003 Sep;64(3):610-8. [PubMed:12920197]
  5. Miwa M, Tsukahara S, Ishikawa E, Asada S, Imai Y, Sugimoto Y: Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants. Int J Cancer. 2003 Dec 10;107(5):757-63. [PubMed:14566825]
  6. Imai Y, Tsukahara S, Ishikawa E, Tsuruo T, Sugimoto Y: Estrone and 17beta-estradiol reverse breast cancer resistance protein-mediated multidrug resistance. Jpn J Cancer Res. 2002 Mar;93(3):231-5. [PubMed:11927002]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name
SLCO1B1
Uniprot ID
Q9Y6L6
Uniprot Name
Solute carrier organic anion transporter family member 1B1
Molecular Weight
76447.99 Da
References
  1. Tamai I, Nozawa T, Koshida M, Nezu J, Sai Y, Tsuji A: Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C. Pharm Res. 2001 Sep;18(9):1262-9. [PubMed:11683238]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34